...
首页> 外文期刊>Journal of Cancer Research and Therapeutics >The detection and significance of T cells in nasopharyngeal carcinoma patients
【24h】

The detection and significance of T cells in nasopharyngeal carcinoma patients

机译:鼻咽癌患者T细胞的检测及其意义

获取原文
           

摘要

Aim of Study: Nasopharyngeal carcinoma (NPC) is by far the most common malignant tumor of the nasopharynx and is suggested to be related to immune system dysfunction. T cells play a central role in the cell-mediated immunity. However, how the T cells vary during the NPC treatment is still unclear. Materials and Methods: We divided the NPC patients into previously untreated, partial remission, complete remission, and relapse groups. Healthy controls were those without any autoimmune diseases, cancer, or recent infection. We used flow cytometry to detect the changes in T cell subsets. Results: We found the quantity (%) of CD4+ CD25+ CD127low/? Treg regulatory T cells and CD8+ CD28? T cells were obviously increased in NPC previously untreated, partial remission, and relapse groups. There was no difference in these two subsets between complete remission groups and healthy controls. In addition, the quantity (%) of CD3+ CD4+ and CD8+ CD28+ effector T cells were reduced in NPC previously untreated, partial remission, and relapse groups. There was no difference in these two subsets between complete remission groups and healthy controls. Conclusions: Our research determines the changes of T cell subsets in different stages of NPC.
机译:研究目的:鼻咽癌(NPC)是迄今为止最常见的鼻咽恶性肿瘤,被认为与免疫系统功能障碍有关。 T细胞在细胞介导的免疫中起关键作用。但是,尚不清楚在NPC治疗期间T细胞如何变化。材料和方法:我们将NPC患者分为先前未治疗的患者,部分缓解的患者,完全缓解的患者和复发的患者。健康对照是没有任何自身免疫性疾病,癌症或近期感染的对照。我们使用流式细胞仪检测T细胞亚群的变化。结果:我们发现CD4 + CD25 + CD127 low /? Treg调节性T细胞和CD8 + < / sup> CD28 ? T细胞在未治疗,部分缓解和复发的NPC中明显增加。完全缓解组和健康对照组之间的这两个亚组没有差异。另外,CD3 + CD4 + 和CD8 + CD28 + 效应T细胞的数量(%)为减少了先前未治疗的NPC,部分缓解和复发组的NPC。完全缓解组和健康对照组之间的这两个亚组没有差异。结论:我们的研究确定了NPC不同阶段中T细胞亚群的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号